CA3118367A1 - Treatment and diagnosis of autoantibody-mediated eye diseases - Google Patents

Treatment and diagnosis of autoantibody-mediated eye diseases Download PDF

Info

Publication number
CA3118367A1
CA3118367A1 CA3118367A CA3118367A CA3118367A1 CA 3118367 A1 CA3118367 A1 CA 3118367A1 CA 3118367 A CA3118367 A CA 3118367A CA 3118367 A CA3118367 A CA 3118367A CA 3118367 A1 CA3118367 A1 CA 3118367A1
Authority
CA
Canada
Prior art keywords
ocular
disease
eye
ophthalmic formulation
autoantibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3118367A
Other languages
English (en)
French (fr)
Inventor
Sandeep Jain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois System filed Critical University of Illinois System
Publication of CA3118367A1 publication Critical patent/CA3118367A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3118367A 2018-11-08 2019-11-08 Treatment and diagnosis of autoantibody-mediated eye diseases Pending CA3118367A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862757641P 2018-11-08 2018-11-08
US62/757,641 2018-11-08
US201962855253P 2019-05-31 2019-05-31
US62/855,253 2019-05-31
PCT/US2019/060566 WO2020097528A1 (en) 2018-11-08 2019-11-08 Treatment and diagnosis of autoantibody-mediated eye diseases

Publications (1)

Publication Number Publication Date
CA3118367A1 true CA3118367A1 (en) 2020-05-14

Family

ID=69056109

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3118367A Pending CA3118367A1 (en) 2018-11-08 2019-11-08 Treatment and diagnosis of autoantibody-mediated eye diseases

Country Status (10)

Country Link
US (1) US20220062337A1 (cg-RX-API-DMAC7.html)
EP (1) EP3877406A1 (cg-RX-API-DMAC7.html)
JP (2) JP7624220B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210093274A (cg-RX-API-DMAC7.html)
CN (1) CN113631570B (cg-RX-API-DMAC7.html)
AU (1) AU2019377552B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021008548A2 (cg-RX-API-DMAC7.html)
CA (1) CA3118367A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021005352A (cg-RX-API-DMAC7.html)
WO (1) WO2020097528A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202100002306A1 (it) * 2021-02-03 2022-08-03 Univ Degli Studi Roma La Sapienza Procedimento e kit per la diagnosi in vitro della sindrome da anticorpi anti-fosfolipidi
US11951123B2 (en) * 2022-01-12 2024-04-09 Platform Ophthalmic Innovations, LLC Fortified nutritional lubricating drops for dry eye disease
WO2023201283A2 (en) * 2022-04-13 2023-10-19 The Regents Of The University Of California Methods of producing plasma or serum and uses thereof
WO2024077068A1 (en) * 2022-10-06 2024-04-11 Oklahoma Medical Research Foundation Anti-vimentin antibodies are associated with higher severity of sjögren's syndrome
WO2024136368A1 (ko) * 2022-12-21 2024-06-27 건국대학교 산학협력단 α-2,6-시알산화 면역글로불린의 안구 건조증 또는 염증성 안과 질환의 예방 또는 치료 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984492B2 (en) 2003-09-05 2006-01-10 Talecris Biotherapeutics, Inc. Methods and compositions for treating herpes infections
CA2888519C (en) 2012-10-17 2023-02-21 Liverpool School Of Tropical Medicine Immunomodulatory proteins
US9107906B1 (en) * 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency

Also Published As

Publication number Publication date
WO2020097528A1 (en) 2020-05-14
US20220062337A1 (en) 2022-03-03
MX2021005352A (es) 2021-09-14
KR20210093274A (ko) 2021-07-27
AU2019377552A1 (en) 2021-05-27
AU2019377552B2 (en) 2026-07-23
BR112021008548A2 (pt) 2021-08-03
EP3877406A1 (en) 2021-09-15
JP2022512946A (ja) 2022-02-07
CN113631570B (zh) 2026-06-02
JP2025061211A (ja) 2025-04-10
CN113631570A (zh) 2021-11-09
JP7624220B2 (ja) 2025-01-30

Similar Documents

Publication Publication Date Title
JP7624220B2 (ja) 自己抗体媒介性眼疾患の治療および診断
Phadatare et al. A comprehensive review on dry eye disease: diagnosis, medical management, recent developments, and future challenges
JP7500550B2 (ja) 乾性眼疾患の治療のための眼科用組成物
JP7520851B2 (ja) 緑内障用の組成物および方法
Al-Saedi et al. Dry eye disease: present challenges in the management and future trends
US20210322457A1 (en) Treatment and diagnosis of ocular surface disorders
CN1964719B (zh) 依碳酸氯替泼诺用于制备治疗干眼症的药物的用途
HK1247120A1 (zh) 用於治疗眼部炎性病症含有整联蛋白α4拮抗剂的药物组合物
JP2022512946A5 (cg-RX-API-DMAC7.html)
JP6544806B2 (ja) 眼疾患の治療および診断
US12268706B2 (en) Hyaluronic acid for relief of idiopathic ocular pain
WO2023220676A9 (en) Chemerin-containing formulation for treating dry eye disease
Heiligenhaus et al. Everolimus for the treatment of uveitis refractory to cyclosporine A: a pilot study
RU2845362C2 (ru) Лечение и диагностика опосредованных аутоантителами глазных заболеваний
JP6503085B2 (ja) ドライアイ疾患を治療及び/又は予防するための短い合成ペプチドの使用
EP4640702A1 (en) Use of alpha-2,6-sialylated immunoglobulin in preventing or treating dry eye syndrome or inflammatory eye diseases
US20230134843A1 (en) Treatment of stem cell deficiency
Muna et al. Ocular cicatricial pemphigoid
HK40059775A (en) Methods and compositions for reducing corneal endothelial cell loss
EP3865132A1 (en) Methods and compositions for reducing corneal endothelial cell loss
Shah Evaluation of Rapamycin for the Treatment of Autoimmune-Mediated Dry Eye in a Mouse Model of Sjögren's Syndrome
Saw The role of inflammation and fibroblasts in conjunctival scarring in ocular mucous membrane pemphigoid
HK40007309A (zh) 近视的治疗

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231108

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - SMALL

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241102

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241102

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241102

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250107

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250506

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250507

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250722

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250722

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - SMALL

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251023

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251023

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260413

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260729